AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 69 filers reported holding AKERO THERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is - and the average weighting 1.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $114,816 | -32.8% | 2,270 | -38.0% | 0.00% | – |
| Q2 2023 | $170,932 | +38.5% | 3,661 | +13.5% | 0.00% | – |
| Q1 2023 | $123,388 | -69.7% | 3,225 | -56.6% | 0.00% | -100.0% |
| Q4 2022 | $407,328 | +115.5% | 7,433 | +34.1% | 0.00% | – |
| Q3 2022 | $189,000 | +800.0% | 5,541 | +145.7% | 0.00% | – |
| Q2 2022 | $21,000 | +5.0% | 2,255 | +63.9% | 0.00% | – |
| Q1 2022 | $20,000 | -13.0% | 1,376 | +25.1% | 0.00% | – |
| Q4 2021 | $23,000 | -8.0% | 1,100 | 0.0% | 0.00% | – |
| Q3 2021 | $25,000 | -66.7% | 1,100 | -63.7% | 0.00% | – |
| Q2 2021 | $75,000 | -35.3% | 3,031 | -24.2% | 0.00% | – |
| Q1 2021 | $116,000 | +510.5% | 4,000 | +433.3% | 0.00% | – |
| Q2 2020 | $19,000 | +18.8% | 750 | 0.0% | 0.00% | – |
| Q1 2020 | $16,000 | – | 750 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ATP Life Science Ventures, L.P. | 5,830,203 | $168,435,000 | 13.00% |
| venBio Partners LLC | 2,444,311 | $63,063,000 | 5.57% |
| Versant Venture Management, LLC | 777,727 | $20,065,000 | 2.08% |
| Vivo Capital, LLC | 633,426 | $16,342,000 | 0.73% |
| Redmile Group, LLC | 2,322,557 | $59,922,000 | 0.73% |
| Boxer Capital, LLC | 831,495 | $21,453,000 | 0.69% |
| Integral Health Asset Management, LLC | 85,000 | $2,193,000 | 0.65% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 35,179 | $908,000 | 0.53% |
| HighVista Strategies LLC | 27,739 | $716,000 | 0.46% |
| Cormorant Asset Management, LP | 742,549 | $19,158,000 | 0.46% |